WuXi Biologics
Offering End-to-End Solutions
- About Us
About Us - Services & SolutionsAbout Us
- Investor RelationsAbout Us
- News & ResourcesAbout Us
WuXi XDC Honored with “Most Valuable Pharmaceutical and Healthcare Company” and “Best CFO” Awards
(Shanghai, China, December 13, 2024) —WuXi XDC Cayman Inc. (“WuXi XDC”, or the “Company”, stock code: 2268.HK), a leading global CRDMO (Contract Research, Development, and Manufacturing Organization) specializing in antibody-drug conjugates (ADCs) and other...
WuXi XDC Wins the “Top Investor-Picked Companies” Award, Demonstrating Exceptional Investment Value and Competitive Strength
(Shanghai, China, November 21, 2024) —WuXi XDC Cayman Inc. (“WuXi XDC”, or the “Company”, stock code: 2268.HK), a leading global CRDMO (Contract Research, Development, and Manufacturing Organization) specializing in antibody-drug conjugates (ADCs) and other...
WuXi XDC Named Best CDMO Winner at 2024 World ADC Awards
Shanghai, China, and San Diego, USA, November 8, 2024 – WuXi XDC Cayman Inc. (“WuXi XDC” or the “Company”, stock code: 2268.HK), a leading global CRDMO (Contract Research, Development, and Manufacturing Organization) specializing in antibody-drug conjugates (ADCs) and...
WuXi XDC Receives Morningstar Sustainalytics 2024 ESG “Low Risk” Rating
Shanghai, China, October 30, 2024-WuXi XDC Cayman Inc. (“WuXi XDC” or the “Company”, stock code: 2268.HK), a leading global Contract Research, Development and Manufacturing Organization (“CRDMO”) focused on antibody drug conjugates (ADC) and other bioconjugates, has...
WuXi XDC and Phamadule Morimatsu Achieve Milestone with Successful Shipment of ADC Modular Facilities for Singapore Manufacturing Site
Shanghai, China, October 14, 2024 – In the global biopharmaceutical industry, the innovation and production of antibody-drug conjugates (ADCs) and other bioconjugates(XDCs) are increasingly recognized as critical drivers of industry growth, offering transformative...
Notice:
You are leaving WuXi Biologics Website, after which our Privacy Notice will not apply. Please keep it in mind the protection of your privacy. Are you willing to proceed?